MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$70K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from maturities of shor...
Proceeds (expenses) from sale of...
Stock option compensation to emp...
Others
Negative Cash Flow Breakdown
Disbursements to acquire short-t...
Prepaid expenses and other curre...
Receivables
Operating lease liability
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-04-30
2026-01-31
2025-10-31
2025-07-31
Total operating expenses
2,647
2,716
-
-
Loss from operations
-2,647
-2,716
-
-
Common stock issued to consultants
-
-
-
0
Interest income
111
131
-
-
Net loss
-2,536
-2,585
-2,722
-8,306
Stock option compensation to employees and directors
637
768
859
2,822
Stock options issued to consultants
28
28
52
77
Amortization of operating lease right-of-use asset
10
10
9
27
Amortization of discount on held-to-maturity securities
-24
-47
50
93
Receivables
56
-
0
-173
Prepaid expenses and other current assets
102
135
-707
155
Accounts payable
104
-17
-111
-249
Accrued expenses
159
-715
10
-195
Operating lease liability
-9
-11
-9
-19
Net cash used in operating activities
-1,741
-2,610
-1,255
-5,918
Disbursements to acquire short-term investments
12,110
12,532
7,660
36,700
Proceeds from maturities of short-term investments
12,532
13,760
8,314
40,912
Net cash provided by investing activities
422
1,228
654
4,212
Proceeds (expenses) from sale of common stock in an at-the-market offering, net of offering expenses of 135 and 51, respectively
2,870
-
454
1,924
Proceeds from sale of common stock pursuant to an employee stock purchase plan
4
-
3
4
Net proceeds (expenses) from an at-the-market offering
-
1,625
-
-
Net (costs) proceeds from exercise of stock options
-
-
-105
-
Proceeds from exercise of stock options
0
58
-
2
Net cash provided by financing activities
1,249
1,685
350
1,930
Net increase in cash and cash equivalents
-70
303
-251
224
Cash and cash equivalents at beginning of period
1,547
1,244
1,271
-
Cash and cash equivalents at end of period
1,477
1,547
1,244
-
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds (expenses) from
sale of common stock...
$2,870K
Proceeds from maturities
of short-term...
$12,532K
Proceeds from sale of
common stock pursuant...
$4K
Net cash provided by
financing activities
$1,249K
Net cash provided by
investing activities
$422K
Canceled cashflow
$1,625K
Canceled cashflow
$12,110K
Net increase in cash
and cash...
-$70K
Canceled cashflow
$1,671K
Stock option
compensation to employees and...
$637K
Accrued expenses
$159K
Accounts payable
$104K
Stock options issued
to consultants
$28K
Amortization of discount on
held-to-maturity securities
-$24K
Amortization of operating
lease right-of-use...
$10K
something is missing
-$1,625K
Disbursements to acquire
short-term investments
$12,110K
Net cash used in
operating activities
-$1,741K
Canceled cashflow
$962K
Interest income
$111K
Net loss
-$2,536K
Canceled cashflow
$111K
Prepaid expenses and
other current assets
$102K
Receivables
$56K
Operating lease liability
-$9K
Loss from operations
-$2,647K
Total operating
expenses
$2,647K
Buy us a coffee
Anixa Biosciences Inc (ANIX)
Anixa Biosciences Inc (ANIX)